4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Optimistic Analyst Target Price Increase

Core Insights - 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a clinical-stage company focused on gene therapy, utilizing adeno-associated virus vectors for treatments in ophthalmology, cardiology, and pulmonology [1] - The company has several candidates in clinical trials, including 4D-125 for X-linked retinitis pigmentosa and 4D-310 for Fabry disease, along with investigational new drug candidates like 4D-150 for wet age-related macular degeneration [1] Price Target and Analyst Sentiment - The stock's consensus target price has increased from $16.33 to $21.5 over the past year, indicating growing optimism among analysts [2][5] - Wall Street analysts have set an average price target for FDMT, suggesting a potential upside of 208.5%, supported by positive trends in earnings estimate revisions [3][5] - Factors contributing to this positive outlook include advancements in clinical trials and successful collaborations with partners such as uniQure and Roche [2][5] Monitoring Developments - Investors are advised to monitor upcoming news or results from FDMT's clinical trials, as these could further influence the stock's target price and market performance [4]